Berry Genomics Co Ltd (SHE:000710) — Market Cap & Net Worth
Market Cap & Net Worth: Berry Genomics Co Ltd (000710)
Berry Genomics Co Ltd (SHE:000710) has a market capitalization of $406.61 Million (CN¥2.78 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13455 globally and #4021 in its home market, demonstrating a -3.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Berry Genomics Co Ltd's stock price CN¥7.86 by its total outstanding shares 353521465 (353.52 Million). Review 000710 total liabilities to assess the company's total debt and financial obligations.
Berry Genomics Co Ltd Market Cap History: 2015 to 2026
Berry Genomics Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.11 Billion to $406.61 Million (-11.13% CAGR).
Berry Genomics Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Berry Genomics Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.41x
Berry Genomics Co Ltd's market cap is 0.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.11 Billion | $230.06 Million | -$13.01 Million | 9.19x | N/A |
| 2016 | $2.45 Billion | $247.38 Million | -$4.19 Million | 9.91x | N/A |
| 2017 | $2.92 Billion | $1.17 Billion | $232.75 Million | 2.49x | 12.53x |
| 2018 | $1.65 Billion | $1.44 Billion | $268.09 Million | 1.15x | 6.16x |
| 2019 | $1.89 Billion | $1.62 Billion | $390.62 Million | 1.17x | 4.85x |
| 2020 | $1.97 Billion | $1.54 Billion | $210.67 Million | 1.28x | 9.35x |
| 2021 | $1.00 Billion | $1.42 Billion | -$109.86 Million | 0.71x | N/A |
| 2022 | $590.25 Million | $1.37 Billion | -$252.25 Million | 0.43x | N/A |
| 2023 | $595.94 Million | $1.15 Billion | -$427.20 Million | 0.52x | N/A |
| 2024 | $437.13 Million | $1.08 Billion | -$192.43 Million | 0.41x | N/A |
Competitor Companies of 000710 by Market Capitalization
Companies near Berry Genomics Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Berry Genomics Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #131 globally with a market cap of $174.56 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $125.14 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #621 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #664 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #131 | Thermo Fisher Scientific Inc | NYSE:TMO | $174.56 Billion | $464.61 |
| #189 | Danaher Corporation | NYSE:DHR | $125.14 Billion | $177.17 |
| #621 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $562.09 |
| #664 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Berry Genomics Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Berry Genomics Co Ltd's market cap moved from $2.11 Billion to $ 406.61 Million, with a yearly change of -11.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥406.61 Million | -30.38% |
| 2025 | CN¥584.05 Million | +33.61% |
| 2024 | CN¥437.13 Million | -26.65% |
| 2023 | CN¥595.94 Million | +0.96% |
| 2022 | CN¥590.25 Million | -41.19% |
| 2021 | CN¥1.00 Billion | -49.03% |
| 2020 | CN¥1.97 Billion | +3.99% |
| 2019 | CN¥1.89 Billion | +14.73% |
| 2018 | CN¥1.65 Billion | -43.41% |
| 2017 | CN¥2.92 Billion | +18.90% |
| 2016 | CN¥2.45 Billion | +15.97% |
| 2015 | CN¥2.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Berry Genomics Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $406.61 Million USD |
| MoneyControl | $406.61 Million USD |
| MarketWatch | $406.61 Million USD |
| marketcap.company | $406.61 Million USD |
| Reuters | $406.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Berry Genomics Co Ltd
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcri… Read more